Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats

References

• Choi JS, Choi DH. (2013). Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Pharmazie 68:882–8.
   PubMed Web of Science ®Google Scholar
• Eid HM, Haddad PS. (2017). The antidiabetic potential of quercetin: underlying mechanisms. Curr Med Chem 24:355–64.
   PubMed Web of Science ®Google Scholar
• Gruse J, Gors S, Tuchscherer A, et al. (2015). The effects of oral quercetin supplementation on splanchnic glucose metabolism in 1-week-old calves depend on diet after birth. J Nutr 145:2486–95.
   PubMed Web of Science ®Google Scholar
• Hatahet T, Morille M, Hommoss A, et al. (2016). Dermal quercetin smartCrystals®: formulation development, antioxidant activity and cellular safety. Eur J Pharm Biopharm 102:51–63.
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhao J, Jian W, Wang G. (2017). Effects of verapamil on the pharmacokinetics of dihydromyricetin in rats and its potential mechanism. Xenobiotica 1–6 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Jana S, Rastogi H. (2017). Effects of caffeic acid and quercetin on in vitro permeability, metabolism and in vivo pharmacokinetics of melatonin in rats: potential for herb-drug interaction. Eur J Drug Metab Pharmacokinet 42:781–91.
   PubMed Web of Science ®Google Scholar
• Jia FF, Tan ZR, McLeod HL, et al. (2016). Effects of quercetin on pharmacokinetics of cefprozil in Chinese-Han male volunteers. Xenobiotica 46:896–900.
   PubMed Web of Science ®Google Scholar
• Joyce H, McCann A, Clynes M, Larkin A. (2015). Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism. Expert Opin Drug Metab Toxicol 11:795–809.
   PubMed Web of Science ®Google Scholar
• Kaur G, Invally M, Chintamaneni M. (2016). Influence of piperine and quercetin on antidiabetic potential of curcumin. J Complement Integr Med 13:247–55.
   PubMedGoogle Scholar
• Kim RB, Fromm MF, Wandel C, et al. (1998). The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289–94.
   PubMed Web of Science ®Google Scholar
• Kimura O, Fujii Y, Haraguchi K, et al. (2016). Effect of quercetin on the uptake and efflux of aristolochic acid I from Caco-2 cell monolayers. J Pharm Pharmacol 68:883–9.
   PubMed Web of Science ®Google Scholar
• Klishadi MS, Zarei F, Hejazian SH, et al. (2015). Losartan protects the heart against ischemia reperfusion injury: sirtuin3 involvement. J Pharm Pharm Sci 18:112–23.
   PubMedGoogle Scholar
• Kobayashi M, Takagi M, Fukumoto K, et al. (2008). The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 23:115–19.
   PubMed Web of Science ®Google Scholar
• Li H, Liu L, Xie L, et al. (2016b). Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism. Pharm Biol 54:2886–94.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang K, Zheng J, et al. (2014). Interactions of the active components of Punica granatum (pomegranate) with the essential renal and hepatic human solute carrier transporters. Pharm Biol 52:1510–17.
   PubMed Web of Science ®Google Scholar
• Li B, Yang M, Liu JW, Yin GT. (2016a). Protective mechanism of quercetin on acute myocardial infarction in rats. Genet Mol Res 15:15017117.
   PubMed Web of Science ®Google Scholar
• Li Y, Yao J, Han C, et al. (2016c). Quercetin, inflammation and immunity. Nutrients 8:167.
   PubMed Web of Science ®Google Scholar
• Moreno L, Puerta E, Suarez-Santiago JE, et al. (2017). Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease. Int J Pharm 517:50–7.
   PubMed Web of Science ®Google Scholar
• Nguyen MA, Staubach P, Wolffram S, Langguth P. (2014). Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci 61:54–60.
   PubMed Web of Science ®Google Scholar
• Oboh G, Ademosun AO, Ogunsuyi OB. (2016). Quercetin and its role in chronic diseases. Adv Exp Med Biol 929:377–87.
   PubMed Web of Science ®Google Scholar
• Palle S, Neerati P. (2017). Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases. Pharmacol Rep 69:365–70.
   PubMed Web of Science ®Google Scholar
• Ravikumar Reddy D, Khurana A, Bale S, et al. (2016). Natural flavonoids silymarin and quercetin improve the brain distribution of co-administered P-gp substrate drugs. Springerplus 5:1618.
   PubMedGoogle Scholar
• Rincon J, Correia D, Arcaya JL, et al. (2015). Role of angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension. Life Sci 124:81–90.
   PubMed Web of Science ®Google Scholar
• Soldner A, Benet LZ, Mutschler E, Christians U. (2000). Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol 129:1235–43.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang X, Liu F, et al. (2017). The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism. Pharm Biol 55:1863–7.
   PubMed Web of Science ®Google Scholar
• Wen F, Shi M, Bian J, et al. (2015). Identification of natural products as modulators of OATP2B1 using LC-MS/MS to quantify OATP-mediated uptake. Pharm Biol 54:293–302.
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Stevens JC. (1992). The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22:1–21.
   PubMed Web of Science ®Google Scholar
• Xiaoyang L, Chenming N, Chengqing L, Tao L. (2015). Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G. Afr Health Sci 15:590–3.
   PubMed Web of Science ®Google Scholar
• Yang SH, Cho YA, Choi JS. (2011a). Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin 32:967–72.
   PubMed Web of Science ®Google Scholar
• Yang SH, Choi JS, Choi DH. (2011b). Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88:1–9.
   PubMed Web of Science ®Google Scholar
• Yasar U, Babaoglu MO, Bozkurt A. (2008). Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin Pharmacol Toxicol 103:176–9.
   PubMed Web of Science ®Google Scholar
• Ye L, Wang T, Tang L, et al. (2011). Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci 100:5007–17.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhang H, Ma W, et al. (2013). Influence of compound Danshen tablet on the pharmacokinetics of losartan and its metabolite EXP3174 by liquid chromatography coupled with mass spectrometry. Biomed Chromatogr 27:1219–24.
   PubMed Web of Science ®Google Scholar
• Yun CH, Lee HS, Lee H, et al. (1995). Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug Metab Dispos 23:285–9.
   PubMed Web of Science ®Google Scholar
• Zaidenstein R, Soback S, Gips M, et al. (2001). Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 23:369–73.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Liu Y, Cheng J, et al. (2007). Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci 10:496–503.
   PubMed Web of Science ®Google Scholar